Search results for: 'optimization for plan grid'

23 Oct 2020  |  Global  |  Market Research

Supply Chain Optimization and Decentralized Manufacturing to Expand the Contract Cell and Gene Therapy Manufacturing Market, 2020–2026

Automation Deployed to Contain Cost of Goods Sold and Vector Manufacturing Standardization will Create New Growth Opportunities

Infographics

×

The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space. While the science behind the therapy has grown by leaps and bounds on the back of decades worth of research, manufacturing has unfortunately lagged behind. To fully harness the curative potential of these therapies and ensure greater reach and a...

Therapeutically more effective drugs for the treatment of chronic diseases represents a crucial need. Biosimilars and biobetters offer the possibility to lower the cost of treating a variety of chronic diseases. In particular, biosimilars are the less expensive option; however, biobetters have demonstrated to be more effective, even over longer per...

The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approach...

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

20 Dec 2022  |  Global  |  Technology Research

Advances and Growth Opportunities in RNA Vaccines

Technology Innovations and Investments Bolster Next-generation Prophylactic and Therapeutic RNA Vaccines

Infographics

×

RNA therapeutics and vaccines have been around for a long time, but the COVID-19 pandemic enabled their mass-market commercialization. Industry players saw mRNA vaccines developed for COVID-19 as effective for reducing the impact of the SARS-CoV-2 virus in populations. Moderna emerged as the first player to develop and commercialize an mRNA vaccine...

21 Aug 2020  |  Global  |  Market Research

Hybridization of Clinical Trial Designs Reviving Global CRO Market Post-pandemic, 2019–2024

Patient-centric and Safety-focused Logistical Solutions will Create New Growth Opportunities

Infographics

×

In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new t...

The increasing disposable incomes in developing countries have contributed to a sedentary lifestyle worldwide. The advent of food delivery apps has also increased accessibility to various culinary delights. These factors have contributed mainly to obesity and other lifestyle diseases. People with a body mass index (BMI) of more than or equal to...

Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure ...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...